Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NC100150

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ferumoxtran-10

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging.
Five types of superparamagnetic iron oxide (SPIO), i.e. Ferumoxides (Feridex(®) IV, Berlex Laboratories), Ferucarbotran (Resovist… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging
The purpose of this study was to determine the cellular distribution and degradation in rat liver following intravenous injection… Expand
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry.
PURPOSE To investigate the physiological origins responsible for the varying blood oxygenation level dependent (BOLD) magnetic… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
PURPOSE To define the diagnostic potential of magnetic resonance (MR) imaging enhanced with ultrasmall superparamagnetic iron… Expand
Is this relevant?
2000
2000
NC100150 Injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography.
A preparation of monocrystalline iron oxide nanoparticles with an oxidized starch coating, currently in clinical trials (NC100150… Expand
Is this relevant?
2000
2000
Three-dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 injection (Clariscan).
The influence of increasing doses of NC100150 Injection (Clariscantrade mark) and echo times on visualization of pulmonary… Expand
Is this relevant?
1999
1999
Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography.
In this Phase I clinical study, a novel ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed… Expand
Is this relevant?
1999
1999
High-resolution magnetic resonance coronary angiography of the entire heart using a new blood-pool agent, NC100150 injection: comparison with invasive x-ray angiography in pigs.
Recent developments of novel magnetic resonance intravascular contrast agents with low T1 in blood and a long intravascular half… Expand
  • figure 1
  • figure 2
  • table I
  • table 2
Is this relevant?
1999
1999
Characterization of t1 relaxation and blood-myocardial contrast enhancement of NC100150 injection in cardiac MRI.
A new ultrasmall superparamagnetic iron oxide (Clariscan; NC100150 Injection) was studied in domestic farm pigs. The T1 effects… Expand
Is this relevant?
1999
1999
Use of the intravascular contrast agent NC100150 injection in spin-echo and gradient-echo imaging of the heart.
This is the first study of the intravascular iron oxide particle contrast agent, NC100150 Injection (Nycomed Imaging AS, Oslo… Expand
  • table I
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE